News & Updates

Current Food and Drug Administration (FDA)-approved intragastric balloon (IGB) systems, the gas-filled IGB (Obalon) and the fluid-filled IGB (Orbera), demonstrate similar effectiveness for the treatment of obesity, as shown in a recent study.

Researchers from the Chinese University of Hong Kong (CUHK) have discovered PDE1A rs10171703 as a novel genetic marker for coronary heart disease (CHD) in Chinese patients with type 2 diabetes mellitus (T2DM), indicating its potential utility for predicting CHD risk in this patient population.

Using alternative anthropometric measurements, a post hoc analysis that used data from the PARADIGM-HF* trial debunked the BMI-related ‘obesity paradox’ in a large cohort of patients with chronic heart failure with reduced ejection fraction (HFrEF).

Diabetes is the most prevalent cause of blindness in working-age individuals. However, 64 percent of Malaysians are not aware that diabetes can lead to eye problems. On the other hand, heart disease, kidney disease, and amputations are some of the health issues that come to mind when diabetes is mentioned.